Sio Capital Management LLC Decreased Emergent Biosolutions INC (EBS) Stake by $6.32 Million; Market Valuation Declined

Emergent BioSolutions Inc. (NYSE:EBS) LogoInvestors sentiment decreased to 1 in 2019 Q2. Its down 0.04, from 1.04 in 2019Q1. It dropped, as 37 investors sold EBS shares while 66 reduced holdings. 27 funds opened positions while 76 raised stakes. 43.78 million shares or 2.93% more from 42.54 million shares in 2019Q1 were reported. Savings Bank Of America De stated it has 0% in Emergent BioSolutions Inc. (NYSE:EBS). Tarbox Family Office owns 43 shares for 0% of their portfolio. Shell Asset has 12,479 shares for 0.01% of their portfolio. Fmr Lc has invested 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Missouri-based Stifel has invested 0% in Emergent BioSolutions Inc. (NYSE:EBS). Qs Investors holds 0.04% or 75,167 shares in its portfolio. Ny State Teachers Retirement Sys has 30,616 shares for 0% of their portfolio. Deutsche Commercial Bank Ag has 0% invested in Emergent BioSolutions Inc. (NYSE:EBS). State Street has invested 0.01% in Emergent BioSolutions Inc. (NYSE:EBS). Rafferty Asset Management invested in 0.09% or 106,398 shares. Matarin Capital Management stated it has 143,509 shares or 0.5% of all its holdings. New Jersey-based Prudential has invested 0.03% in Emergent BioSolutions Inc. (NYSE:EBS). Advsr Asset Mgmt Incorporated holds 0% or 282 shares in its portfolio. Sterling Llc holds 0.01% in Emergent BioSolutions Inc. (NYSE:EBS) or 26,674 shares. 532,490 were accumulated by Manufacturers Life Insurance The.

Sio Capital Management Llc decreased its stake in Emergent Biosolutions Inc (EBS) by 73.13% based on its latest 2019Q2 regulatory filing with the SEC. Sio Capital Management Llc sold 131,756 shares as the company’s stock declined 15.65% . The institutional investor held 48,400 shares of the health care company at the end of 2019Q2, valued at $2.34 million, down from 180,156 at the end of the previous reported quarter. Sio Capital Management Llc who had been investing in Emergent Biosolutions Inc for a number of months, seems to be less bullish one the $2.73B market cap company. The stock decreased 2.42% or $1.31 during the last trading session, reaching $52.83. About 283,380 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has declined 16.70% since September 13, 2018 and is downtrending. It has underperformed by 16.70% the S&P500.

Sio Capital Management Llc, which manages about $116.75 million and $414.77 million US Long portfolio, upped its stake in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) by 72,400 shares to 151,553 shares, valued at $11.00 million in 2019Q2, according to the filing. It also increased its holding in Hill (NYSE:HRC) by 32,500 shares in the quarter, for a total of 42,182 shares, and has risen its stake in Wellcare Health Plans Inc (NYSE:WCG).

Analysts await Emergent BioSolutions Inc. (NYSE:EBS) to report earnings on November, 7. They expect $0.73 EPS, up 32.73 % or $0.18 from last year’s $0.55 per share. EBS’s profit will be $37.67M for 18.09 P/E if the $0.73 EPS becomes a reality. After $0.12 actual EPS reported by Emergent BioSolutions Inc. for the previous quarter, Wall Street now forecasts 508.33 % EPS growth.

More notable recent Emergent BioSolutions Inc. (NYSE:EBS) news were published by: which released: “Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors – GlobeNewswire” on February 12, 2019, also with their article: “Emergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile – GlobeNewswire” published on May 15, 2019, published: “New coverage – healthcare – Seeking Alpha” on September 12, 2019. More interesting news about Emergent BioSolutions Inc. (NYSE:EBS) were released by: and their article: “Opiant Pharmaceuticals: A Hidden Gem With Upcoming Catalyst – Seeking Alpha” published on September 10, 2019 as well as‘s news article titled: “Emergent Biosolutions: Leader In The Public Health Threats Space – Seeking Alpha” with publication date: February 28, 2019.

Emergent BioSolutions Inc. (NYSE:EBS) Ratings Coverage

Among 2 analysts covering Emergent Biosolutions (NYSE:EBS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Emergent Biosolutions has $6500 highest and $6400 lowest target. $64.50’s average target is 22.09% above currents $52.83 stock price. Emergent Biosolutions had 3 analyst reports since April 6, 2019 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, September 4 by Wells Fargo.

Emergent BioSolutions Inc. (NYSE:EBS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.